SPACEGEN -Colorectal Cancer Related Gene Mutation Detection Kit（Next Generation Sequencing）

The risk of colorectal cancer is closely related to lifestyle. Increased intake of food from animals and overweight due to sedentary are associated with the risk of colorectal cancer. Other risk factors include alcohol intake, smoking, eating red or processed meat. Proper supplementation of calcium, cereals, fiber and dairy products can reduce its risk. In recent years, with the improvement of social and economic level. The overall incidence rate and mortality rate of colorectal cancer showed a significant upward trend, and the proportion of colorectal cancer increased year by year.

Application of molecular detection in colorectal cancer:

With the development of deep research and detection level of tumor related molecular markers such as RAS, BRAF, mismatch repair / microsatellite instability (MMR / MSI), reasonable detection technology and application have become an important part of clinical practice.

Core Technology:RingCap®

Applicable Disease:Colorectal Cancer

Instruments Validated:Illumina, MGI, etc.

Sample Type:Tumor tissue, Ascites

Qualification:ISO13485 certificate, CAP，CE marking

 Pack Size:16 Tests/Kit,32 Tests/Kit

1.Before adjuvant chemotherapy for resectable non-mCRC patients : the use of this test has a suggestive effect on the selection of adjuvant chemotherapy regimens ;
2.Unresectable non-mCRC patients before treatment decision-making : using this test, suggesting conversion therapy or palliative treatment drugs ;
3.All patients with mCRC : use this test before comprehensive treatment, and formulate individualized treatment plans based on RAS / BRAF gene mutation and MSI status ;
4.For mCRC patients who failed standard treatment : use this test to find suitable targeted or immunotherapy drugs ;
5.All patients with clinically suspected Lynch syndrome : Lynch screening was performed using this test.

1、The detection of RAS, BRAF, HER2 and other gene mutation status suggests the use of anti-EGFR, BRAF/MEK inhibitor, HER2 inhibitor and other targeted drugs, and also has prognostic significance for CRC patients

2、.The detection of chemotherapy-related genes such as UGT1A1 and DPYD can guide the treatment of CRC patients with irinotecan, fluorouracil, capecitabine, tegafur and other chemotherapy drugs.

3、MSI status suggested the efficacy of immune checkpoint inhibitors.

4、The detection of TP53 tumor suppressor gene provides a reference for the prognosis evaluation of patients and the clinical trials of drugs such as AZD1775.

5、MSI and BRAF V600E suggest the risk of Lynch syndrome.

1.Ease of Use: Using RingCap ® proprietary technology, the database construction method is simple, the operation steps are few, and the turn around time is short.

2.MSI status detection : MSI detection uses 34 single nucleotide sites, which effectively avoids the problem of polynucleotide polymorphism and can meet the needs of single sample detection.

3.High Sensitivity: The sensitivity  tissue can reach up to 1%, blood up to 0.5%.

4.Comprehensive Coverage: Covers the CRC guidelines and consensus recommended genes and some optional genes, as well as MSI status